Compare CDW Corp. (CDW) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CDW Corp. vs Zimmer Biomet Holdings Inc — how do they compare? CDW Corp. trades at $136.55 (market cap $16.92B), while Zimmer Biomet Holdings Inc trades at $96.54 (market cap $18.55B). The key difference: CDW Corp. and Zimmer Biomet Holdings Inc are close in size by market cap, and CDW Corp. pays the higher dividend (1.86%). Which is the better fit depends on your goals.
| CDW | ZBH | |
|---|---|---|
Market Cap | $16.92B | $18.55B |
Sector | Technology | Health |
52-Week High | $170.77 | $107.71 |
52-Week Low | $99.30 | $79.58 |
Enterprise Value | $22.52B | $25.61B |
Dividend Yield | 1.86% | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CDW trades at $135.79, down 0.47% on the day, with a bearish technical signal. The stock shows strong profitability with a 44.01% ROE and trades at a P/E of 16.27. Recent Q2 2026 earnings beat expectations with EPS of $2.91, driven by 10% revenue growth, though margin pressures were noted. Analyst consensus is bullish with a $148.67 price target. The company maintains a solid balance sheet with a debt-to-asset ratio of 39.8% as of 2024.
The outlook for CDW is positive due to AI and infrastructure demand, but margin compression and a CFO transition in 2027 pose risks. Upside potential exists if the company meets Q3 2026 EPS expectations of $2.91 and sustains revenue growth. Key risks include competitive pressures and macroeconomic volatility affecting IT spending.
ZBH trades at $96.04, down 1.78% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. Recent Q2 2026 earnings beat expectations with EPS of $2.07 versus $2.01 expected, and the company raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23 billion and a net income margin of 8.56%.
The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and debt levels, with the debt-to-asset ratio rising to 32.57% in 2025. Analyst sentiment is mixed with 40% buy ratings, offering a potential 7.8% upside to the consensus target, though investors should monitor margin trends and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CDW Corp.
CDW Corp is a value-added reseller operating in the U.S. (95% of sales) and Canada (5%). The company has more than 100,000 products on its line of cards that range from notebooks to data center software. Roughly half of CDW's revenue comes from midsize and large businesses, with the remaining from small businesses, government agencies, education institutions, and health-care organizations.
Read more on CDW →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
